D.R. Horton (NYSE:DHI) Q4 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsMichael Rehaut - Executive DirectorStephen Kim - Senior Managing DirectorAlan Ratner - Managing Director of Equity ResearchJessica Hansen - SVP of CommunicationsTrevor Allinson - DirectorMike Murray - COOJade Rahmani - Managing DirectorRafe Jadrosich - Managing DirectorMike Dahl - Managing Director of Equity ResearchSam Reid - Executive Director Equity Research of Home Builders & Building ProductsAlex Rygiel - Mana ...

Repligen (NasdaqGS:RGEN) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsDoug Schenkel - Managing Director and Head of Life Science Tools and DiagnosticsJason Garland - CFOCasey Woodring - VP of Equity ResearchOlivier Loeillot - President and CEOBrandon Couillard - Managing DirectorDaniel Markowitz - VPDan Arias - Managing DirectorLuke Sergott - Director of Healthcare Equity ResearchJacob Johnson - VP of Investor RelationsConference Call ParticipantsAnna Snopkowski - Equity Research A ...

Financial Data and Key Metrics Changes - Revenue increased by 7% year over year, exceeding $1.1 billion [3][4] - Adjusted EPS was $0.85, surpassing the high end of the projected range by $0.10 [3] - Adjusted EBITDA totaled $225 million, with $215 million excluding oil and gas rights, marking a 19% year-over-year improvement [14][3] - Adjusted EBITDA margin exceeded 20%, the highest since the pandemic [3][4] - Cash generated from operations year to date reached $299 million, a $273 million improvement from last year [4][14] Business Line Data and Key Metrics Changes - High Performance Materials & Components (HPMC) segment margins were above 24%, while Advanced Alloys & Solutions (AANS) segment margins were above 17% [4][15] - Aerospace and Defense (A&D) revenue rose 21% year over year, accounting for 70% of total revenue [5][6] - Jet engine revenue, which constitutes 39% of total revenue, grew 19% year over year [6][8] - Airframe sales increased by 9% year over year, supported by Boeing and Airbus production ramps [7][8] - Defense revenue surged 51% year over year, reflecting broad-based strength across various defense programs [9][10] Market Data and Key Metrics Changes - Jet engine growth is expected to exceed 20% for the full year, with Q4 growth anticipated in the high single to low double digits [6][8] - Airframe revenues are expected to finish modestly above 2024 levels, with high single-digit growth anticipated next year [8] - Defense markets are projected to continue record performance due to modernization and replenishment programs [10][12] Company Strategy and Development Direction - The company is focused on high-value materials and markets, with 70% of revenue now coming from aerospace and defense [12][20] - Strategic pricing and mix optimization are key levers for growth, with long-term agreements supporting future investments [20][21] - Operational excellence and productivity improvements are driving margin expansion and cash generation [21][22] - The company is committed to disciplined capital deployment, prioritizing high-return investments [13][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong demand in core markets, particularly aerospace and defense [5][20] - The outlook for Q4 and 2026 remains positive, with expectations of sustained growth in A&D [27][60] - The company is well-positioned to capitalize on long-term growth opportunities, supported by strong customer relationships and proprietary materials [12][20] Other Important Information - The company plans to continue monetizing non-core assets while maintaining disciplined capital investments [15][18] - The CFO, Don Newman, is set to retire after Q4, with a search for his successor underway [19] Q&A Session Summary Question: What has changed since Q2 to drive the revised outlook and guidance increase? - Management noted stronger than expected A&D performance, particularly in defense, contributing to the guidance increase [26][27] Question: What is being done to manage melt capacity for nickel alloys? - The company is focusing on productivity, reliability, and selective expansion of melt capacity to meet growing demand [29][30] Question: What does being the number one source of flat rolled titanium products to Airbus mean for the P&L? - This status translates to increased revenue and higher margins from premium titanium products, with a significant revenue increase expected next year [34][35] Question: What is the expected growth in airframe sales for 2026? - Airframe sales are anticipated to grow at a high single-digit rate, with continued strength in jet engine demand expected [60] Question: How is the company managing working capital improvements? - Improvements in accounts receivable management and inventory efficiencies have contributed to better working capital performance [52][53]

Zebra Technologies (NasdaqGS:ZBRA) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBill Burns - CEOMike Steele - VP of Investor RelationsNathan Winters - CFONone - Company RepresentativeConference Call ParticipantsRob Mason - AnalystGuy Hardwick - AnalystJoe Giordano - AnalystAndrew Buscaglia - AnalystPiyush Avasthy - AnalystJamie Cook - AnalystBrad Hewitt - AnalystKatie Fleischer - AnalystBrian Drab - AnalystTommy Moll - AnalystDamian Karas - AnalystKeith Housum - AnalystOperatorWelc ...

Herc (NYSE:HRI) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsAaron Birnbaum - SVP and COOLeslie Hunziker - SVP of Investor RelationsTami Zakaria - Executive DirectorMircea Dobre - Managing DirectorMark Humphrey - SVP and CFOLarry Silber - President and CEOConference Call ParticipantsNone - AnalystRob Wertheimer - Founding Partner and Machinery AnalystKenneth Newman - VP and Equity Research AnalystOperatorHello and thank you for standing by. My name is Mark and I will be your confer ...

Financial Data and Key Metrics Changes - For Q3 2025, total operating expenses were $15.5 million, down from $19.1 million in Q3 2024, reflecting a 19% year-over-year decrease [17] - Research and development expenses decreased to $9.6 million from $12.3 million year-over-year, driven by lower development costs and improved operating efficiency [17] - General and administrative expenses were $5.9 million, down from $6.8 million in Q3 2024, largely due to reduced stock compensation expense [17] - Net loss for the quarter was $13.6 million, compared to $16.4 million in the prior year period [17] - Cash burn in Q3 was $11.0 million, benefiting from lower operating expenses, with a cash runway projected to extend through 2027 [18][19] Business Line Data and Key Metrics Changes - The company is advancing its TAU proteoform assay and plans to launch an early access program in the first half of 2026 [21] - The early access program will initially focus on TAU, with plans to expand to broad-scale proteomic capabilities in the second half of 2026 [27] Market Data and Key Metrics Changes - The company completed a market study involving over 250 decision-makers across North America and Europe, confirming strong interest in the Nautilus platform [14] - Customers view the Nautilus platform as uniquely differentiated from current technologies, with a strong willingness to invest in its solutions [15] Company Strategy and Development Direction - Nautilus Biotechnology is focused on commercialization and has made significant progress in scientific, platform, and operational priorities [4] - The company aims to validate its platform through early access programs and collaborations with leading research institutions [9][21] - The strategic goal includes launching a broad-scale assay configuration to support commercial activities by late 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the platform's potential to reshape the proteomics landscape, supported by extensive market research [22] - The company anticipates increased operating expenses as it approaches commercialization, with a steady ramp-up expected through 2027 [25][19] Other Important Information - The company is preparing to showcase externally generated TAU data at the World HUPO Conference in November, marking a significant milestone [21] - Nautilus is experiencing increased interest from partners eager to explore new disease areas and proteoform targets [8] Q&A Session Summary Question: What is the expected level of OpEx investment heading into the launch next year? - Management indicated that spending will increase as the company approaches commercialization, with cash projected to last through 2027 [25] Question: Can you elaborate on the funnel being built ahead of early access? - The company plans to launch the early access program in the first half of 2026, starting with TAU, and will expand to broad-scale capabilities in the second half of 2026 [27][29]

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

Avis Budget Group (NasdaqGS:CAR) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsDavid Calabria - Treasurer and SVP of Corporate FinanceBrian Choi - CEODaniel Cunha - EVP and CFOConference Call ParticipantsChris Stathoulopoulos - Senior Equity Research AnalystDan Levy - Senior Equity Research AnalystLizzie Dove - VP and Equity Research AnalystChris Woronka - Senior AnalystRyan Brinkman - Lead Automotive Equity Research AnalystJohn Healy - Managing Director and Senior Research AnalystO ...

NeoGenomics (NasdaqCM:NEO) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsPriya Vedaraman - SVP of FinanceJeff Sherman - CFOTony Zook - CEOWarren Stone - COOConference Call ParticipantsNone - AnalystNone - AnalystNone - AnalystMason Carrico - Research AnalystAndrew Brackmann - AnalystYuko Oku - AnalystDavid Westerberg - AnalystPuneet Souda - AnalystNone - AnalystNone - AnalystPriya VedaramanGood morning everyone and welcome to the NeoGenomics third quarter 2025 financial results call ...

PHINIA (NYSE:PHIN) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsChris Gropp - CFOJake Scholl - Equity Research AssociateKellen Ferris - VP of Investor RelationsBrady Ericson - CEOConference Call ParticipantsJoseph Spak - AnalystBobby Brooks - Senior Research AnalystOperatorGood morning. My name is Audra. I'll be your conference operator today. At this time, I would like to welcome everyone to the PHINIA third quarter 2025 earnings call. Today's conference is being recorded. All lin ...